The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/LMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**NSABP-B-30**: The National Surgical Adjuvant Breast and Bowel Project (NSABP), in NSABP-B-30 found that 4 cycles of concurrent TAC was inferior to sequential AC-T for overall survival and disease-free survival. "This result, combined with the results from the Eiermann study, has huge implications for the length of treatment with this regimen," said NSABP B-30 principal investigator Sandra Swain, MD, from the Washington Cancer Institute, in Washington, DC. "If you are going to use TAC, use 6 cycles," she summarized. The NSABP B30 study is important. Giving TAC for 4 cycles was part of the experimental nature of this study, and these results indicate once again that duration matters within the context of each regimen we use. (Breast Cancer/NSABP/Swain et al.)

**POG-9906**: COG researchers collaborated with researchers from St. Jude Children’s Research Hospital, the University of New Mexico, and NCI as part of the Childhood Cancer TARGET Initiative to discover that the Ikaros gene (IKZF1) is altered in approximately 25% of children with high-risk ALL and is a highly significant independent predictor of poor outcome. The gene expression signature of IKZF1-mutated BCR-ABL1 negative ALL is closely related to that of BCR-ABL1 positive ALL, an observation with potential therapeutic significance. (Leukemia, Myelodysplasia, and Transplantation/COG/Mullighan et al.)
Cooperative Group Abstracts

Breast Cancer

**ACRIN**

Protocol(s): ACRIN-6666

Protocol(s): ACRIN-6657

http://rsna2008.rsna.org/event_display.cfm?em_id=6006524&killterms=Y
Protocol(s): ACRIN-6657, CALGB-150007

Protocol(s): ACRIN-6652

**CALGB**

Protocol(s): ACRIN-6657, CALGB-150007

**ECOG**

http://www.oncotypedx.com/PDFs/dda1aUSCAP2008_Abstract_44.doc
Protocol(s): E2197
http://www.oncotypedx.com/PDFs/6c1c4ASCO_Breast_2008Meeting_Abstract_13.pdf
Protocol(s): E2197

http://www.oncotypedx.com/PDFs/dc227USCAP2008_Abstract_82.doc
Protocol(s): E2197

Protocol(s): E2197

NCCTG

Protocol(s): N9831

NCIC Clinical Trials Group

Protocol(s): JMA17

NSABP

Protocol(s): NSABP-B-30
Protocol(s): NSABP-P-2

Protocol(s): NSABP-B-28

Protocol(s): NSABP-B-30

RTOG

http://www.redjournal.org/article/S0360-3016(08)00990-5/fulltext
Protocol(s): RTOG-0319

SWOG

Protocol(s): S9313A, INT-0137, S9313A-ICSC

CNS Cancer

COG

Protocol(s): INT-0097, INT-0106
**RTOG**

[http://www.redjournal.org/article/S0360-3016(08)01956-1/fulltext](http://www.redjournal.org/article/S0360-3016(08)01956-1/fulltext)  
Protocol(s): Multiple Trials

Protocol(s): RTOG-0513

[http://www.redjournal.org/article/S0360-3016(08)01000-6/fulltext](http://www.redjournal.org/article/S0360-3016(08)01000-6/fulltext)  
Protocol(s): INT-0149, RTOG-94-02  
Other Participating Group(s): ECOG, EORTC, NCCTG, NCIC, SWOG

Protocol(s): RTOG-0211

Protocol(s): RTOG-0211

Protocol(s): RTOG-98-13  
Other Participating Group(s): ECOG, NCCTG, SWOG
Protocol(s): Multiple Trials


Gastrointestinal Cancer

ACRIN


Protocol(s): ACRIN-6664

RTOG

http://www.redjournal.org/article/S0360-3016(08)01015-8/fulltext
Protocol(s): RTOG-97-04
Other Participating Group(s): ECOG, SWOG

http://www.redjournal.org/article/S0360-3016(08)01482-X/fulltext
Protocol(s): RTOG-R-0012

http://www.redjournal.org/article/S0360-3016(08)01143-7/fulltext
Protocol(s): Multiple Trials

http://www.redjournal.org/article/S0360-3016(08)01013-4/fulltext
Protocol(s): RTOG-97-04
Other Participating Group(s): ECOG, SWOG

SWOG

http://www.redjournal.org/article/S0360-3016(08)01141-3/fulltext
Protocol(s): INT-0144, SWOG-9304A-ICSC
Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC, RTOG
**Genitourinary Cancer**

**RTOG**

http://www.redjournal.org/article/S0360-3016(08)01282-0/fulltext  
Protocol(s): RTOG-0321

http://www.redjournal.org/article/S0360-3016(08)01105-X/fulltext  
Protocol(s): RTOG-92-02

http://www.redjournal.org/article/S0360-3016(08)01112-7/fulltext  
Protocol(s): RTOG-92-02

**SWOG**

Protocol(s): SWOG-4B951

Protocol(s): INT-0086

http://www.redjournal.org/article/S0360-3016(08)01051-1/fulltext  
Protocol(s): INT-0086  
Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC, RTOG
Protocol(s): INT-0086

**Gynecologic Cancer**

**GOG**

Protocol(s): GOG-0210

http://www.igcs.org/Abstract/meeting_2008_81.html
Protocol(s): GOG-0129P

**RTOG**

http://www.redjournal.org/article/S0360-3016(08)01023-7/fulltext
Protocol(s): RTOG-C-0128

http://www.redjournal.org/article/S0360-3016(08)01019-5/fulltext
Protocol(s): RTOG-0418

http://www.redjournal.org/article/S0360-3016(08)01018-3/fulltext
Protocol(s): RTOG-C-0128
Head and Neck Cancer

**RTOG**

Protocol(s): RTOG-0022

[http://www.redjournal.org/article/S0360-3016(08)01055-9/fulltext](http://www.redjournal.org/article/S0360-3016(08)01055-9/fulltext)
Protocol(s): RTOG-0234

[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=60&abstractID=50177](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=60&abstractID=50177)
Protocol(s): RTOG-90-03

Protocol(s): RTOG-0225

Leukemia, Myelodysplasia, and Transplantation

**COG**

Protocol(s): Multiple Trials
Protocol(s): AALL03N1

Protocol(s): Multiple Trials

Protocol(s): CCG-2961, CCG-2941

Protocol(s): POG-9906

Protocol(s): AAML03P1

Protocol(s): CCG-1961

Protocol(s): Multiple Trials
Protocol(s): POG-9404

Protocol(s): POG-9906, AALL0232

Protocol(s): Multiple Trials

Protocol(s): Multiple Trials

Protocol(s): CCG-2891, CCG-2961, CCG-2861, CCG-2941

Protocol(s): CCG-2961

Protocol(s): CCG-1991
Protocol(s): CCG-1991

Protocol(s): AALL0232

Protocol(s): Multiple Trials

Protocol(s): POG-9906

Protocol(s): AAML03P1

Protocol(s): CCG-2961, CCG-2941, AAML03P1

Protocol(s): Multiple Trials
Protocol(s): CCG-1953

Protocol(s): AALL0434

Protocol(s): AALL0031

Protocol(s): AALL0031

Protocol(s): P9407, POG-8398, POG-8493, POG-8821/22, POG-9107, POG-9421

Protocol(s): CCG-2891, AAML03P1, P9407, CCG-1961, CCG-2961
Protocol(s): E2903

Protocol(s): INT-0132

Protocol(s): INT-0132

Protocol(s): INT-0132

Protocol(s): INT-0132

Protocol(s): INT-0132
Protocol(s): INT-0132

**Lung Cancer**

**ACRIN**

Protocol(s): ACRIN-6654

Protocol(s): ACRIN-6654

Protocol(s): ACRIN-6668

http://rsna2008.rsna.org/event_display.cfm?em_id=6011173
Protocol(s): ACRIN-6668

**ECOG**

http://www.oncologymeetings.org/lung/abstracts.htm
Protocol(s): E4599

http://jto.org/pt/re/jto/pdfhandler.01243894-200811001-00003.pdf?sessionid=JMwTMW472pp6QGL01WDK2iHc1YH81Dd5sWXniLiCTFhRmVJN8cybl-103590814718119562880911-1
Protocol(s): E4599
NCI’s Clinical Trials Cooperative Groups National Meetings Report

http://jto.org/pt/re/jto/pdfhandler.01243894-200811001-00003.pdf;jsessionid=JMwTMW472pp6QGL01WDK2fHCy1YH81Dd5sWXnjLjCTFhRmVJN8rybl-1035908147!181195628!8091-1  
Protocol(s): E4599

RTOG

http://www.redjournal.org/article/S0360-3016(08)01243-1/fulltext  
Protocol(s): RTOG-0324

Lymphoma and Plasma Cell Disorders

CALGB

Protocol(s): CALGB-50502

Protocol(s): CALGB-50402

Protocol(s): CALGB-50103

Protocol(s): CALGB-50203
COG

Protocol(s): A5971

Protocol(s): ANHL01P1

Protocol(s): CCG-5961

Protocol(s): AHOD0031

ECOG

Protocol(s): E2A02

Protocol(s): E3404

Jacobus SJ, Kumar SK, Callander NS, Ahonour R, Fonseca R, Siegel OS, Greipp PR, Rajkumar SV: Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03 Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RU) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). Blood 2008; 112(11):Abst. 1740.
Protocol(s): E4A03
Protocol(s): EST-9486

**SWOG**

Protocol(s): SWOG-8819

Protocol(s): S8809-S9800, S9800, S9911, SWOG-8809

Protocol(s): SWOG-8819

Protocol(s): S0313

Protocol(s): S0433, S0016
Other Participating Group(s): CALGB
Sarcoma/Bone and Soft Tissue Cancers

**COG**

Protocol(s): Multiple Trials

Protocol(s): INT-0133

**RTOG**

[http://www.redjournal.org/article/S0360-3016(08)01300-X/fulltext](http://www.redjournal.org/article/S0360-3016(08)01300-X/fulltext)
Protocol(s): RTOG-97-14

Other Participating Group(s): NCCTG

**Other Cancer**

**COG**

Protocol(s): ADVL0319

Protocol(s): Multiple Trials

Protocol(s): Multiple Trials


**RTOG**


Abstracts with DCTD and DCP Investigators


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-74-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=7dbc44c316bcf89b45c31f5d2bc95c0b3&ie=/sdarticle.pdf

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-PB-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=3005a22c8eb2b4f7e78574e7cfb7b473836f6fd&ie=/sdarticle.pdf

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-76-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=7898b1b1d8b574e7cb7b473836f6fd&ie=/sdarticle.pdf

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-75-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=ef30c2ce3b84d8792b36680d3f1f857e&ie=/sdarticle.pdf


http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B75GT-4TRC4G4-BM-1&_cdi=13103&_user=5755111&_orig=search&_coverDate=10%2F31%2F2008&_sk=999939987&view=c&wchp=dGLzVtz-zSkWA&md5=f05ae5f0b27d18a4899c9ed5f3ffe9c9b&ie=/sdarticle.pdf
Activities with DCTD and DCP Investigators


Seibel N, Chen H: Discuss IGF-1R Targeted Therapies for Ewing Sarcoma. COG, SARC, and CTEP Meeting, Rockville, Maryland, Nov, 2008.


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.